Phibro Animal Health Corporation (PAHC) - Stock Analysis
Last updated: Apr 12, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Phibro Animal Health exhibits strong earnings growth, margin expansion, cash flow strength, and a 42% price surge over the last month, making it a hot short-term idea with a solid fundamental and technical growth profile.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Improving margins ⢠High leverage ⢠Inventory risk PAHC's margins and liquidity improved quarter-to-quarter, but high leverage, elevated inventory and softer recent free cash flow mean operational gains must continue to justify its premium multiples.
Price Behavior
Key Price Behavior Insights: ⢠Strong short-term momentum ⢠Tight near-term support ⢠Resistance cluster 59â60 Support Level: $53.30â$53.90 Resistance Level: $59.10â$60.00 PAHC is in a clear shortâterm uptrend after an ~18% rebound from $49.00 to $57.89 over the last month, but clustered support at $53.30â$53.90 and resistance near $59.10â$60.00 make it vulnerable to a shortâterm pullback if momentum stalls.
Sentiment & News
Key News Insights: ⢠Strong share gains ⢠Mixed analyst views ⢠CEO insider sale Phibro (PAHC) has surged ~152% YTD on strong animal-health demand, vaccine and Zoetis MFA integration momentum, but faces mixed analyst ratings and a notable CEO share sale.
AI Summary
The MFA acquisition reframes Phibro as a higherâmargin, growthâoriented consolidatorâif management delivers on MFA integration synergies and sustains pricing/mix gains, EBITDA and FCF should rise materially; however, nearâterm valuation is already pricing much of that upside. Monitor quarterly freeâcashâflow recovery, workingâcapital normalization (inventory levels), and progress on deleveraging as the decisive catalysts that will validate the rerating or trigger a sharp pullback.
Description
Phibro Animal Health Corporation manufactures and sells a range of animal health and mineral nutrition products for livestock, operating through Animal Health, Mineral Nutrition, and Performance Products segments. Its portfolio includes pharmaceutical treatments and vaccines for poultry, swine and cattle, nutritional additives and trace mineral formulations, plus specialty ingredients used in non-food industries. The company distributes products to integrators, feed manufacturers and distributors across North America, Latin America, Europe, the Middle East, Africa and the Asia Pacific from its headquarters in Teaneck, New Jersey.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 2 | Sep 9 | PAHC | Phibro Animal Health Corporation | Phibro Animal Health exhibits strong earnings growth, margin expansion, cash flow strength, and a 42% price surge over the last month, making it a hot short-term idea with a solid fundamental and technical growth profile. | Closed | +12.8% |